A rare disease affects only a small percentage of the population, the reason why they have been neglected for years.

Yet, a common mechanism is shared by many: an inherited mutation that ultimately results in the destabilization of a protein.

Our goal is to tackle this common pathogenic mechanism with the design of disease-specific pharmacological chaperones.

This strategy may be able to correct the phenotype for a plethora of rare syndromes. To that end, we use Chassys™, an NMR based innovative and efficient proprietary Platform Technology approach.

Know more about
pharmacological chaperones

Contact form

Parque Tecnológico de Bizkaia
Edificio 800, 48160 Derio (Bizkaia)
info@atlasmolecularpharma.com
+34 944061300 (ext. 4338)